Is Compounded Tirzepatide Still Legal to Get Online in 2026?
Large-scale compounded tirzepatide is now restricted after the FDA resolved the shortage and moved to close the 503B pathway. Here's exactly what changed — and what your options are today.
The direct answer
As of 2026, routine large-scale compounded tirzepatide is no longer legally available the way it was during the 2022–2024 shortage. The FDA declared the tirzepatide shortage resolved in October 2024 and ended compounding enforcement discretion for outsourcing (503B) facilities on March 19, 2025. On May 1, 2026, the FDA proposed removing tirzepatide from the 503B bulks list entirely, citing no clinical need (91 FR 23431). One narrow exception remains: a state-licensed (503A) pharmacy can still compound tirzepatide for an individual patient when a prescriber documents a specific clinical need an FDA-approved product can't meet — but mass-produced copies are no longer permitted. For most patients in 2026, the legitimate paths are FDA-approved brand-name tirzepatide (Zepbound or Mounjaro) or a clinically appropriate alternative prescribed through a licensed provider.
Regulatory history
What Changed, and When
The window for large-scale compounded tirzepatide closed gradually over 18 months. Here is the exact sequence.
| Date | What happened |
|---|---|
| Oct 2024 | FDA declared the tirzepatide shortage resolved |
| Feb 18, 2025 | Enforcement discretion ended for 503A state-licensed pharmacies |
| Mar 19, 2025 | Enforcement discretion ended for 503B outsourcing facilities — mass compounding effectively ends |
| May 1, 2026 | FDA proposed excluding tirzepatide from the 503B bulks list ("no clinical need" finding) — Federal Register docket 2026-08552, 91 FR 23431 |
| Jun 30, 2026 | Public comment period closes at 11:59 p.m. ET — confirmed per 91 FR 23431 |
| TBD | FDA final determination — no timeline announced; FDA stated only that it "intends to publish" a final determination in the Federal Register after reviewing comments. We will update this page when it publishes. |
Important context: Related litigation challenging the FDA's shortage authority is still working through the 5th Circuit and remains unresolved. This timeline reflects the current regulatory state — not necessarily the final word. Precision Telemed tracks this closely and updates guidance as the situation evolves.
Patient safety
Why the FDA Acted
The FDA's decision rests on patient-safety findings, not just paperwork.
320+ Adverse Event Reports
The FDA logged more than 320 adverse-event reports tied to compounded tirzepatide — including dosing errors from multidose vials, some requiring hospitalization. These reports were a central factor in the agency's decision.
Counterfeit Products Online
Counterfeit and substandard tirzepatide products entered the market through online channels. The FDA issued more than 50 warning letters to compounders and telehealth distributors operating outside legal boundaries.
Affordability Is Not a Clinical Need
The FDA explicitly rejected affordability and access as constituting "clinical need" under compounding law. The legal threshold requires a documented medical reason an approved product cannot meet — not a price difference.
What's still permitted
The Narrow Path That's Still Legal
503A patient-specific compounding still exists — but its scope is precisely defined by law. Most competitor pages get this wrong. Here is exactly what is and isn't permitted.
503A Patient-Specific Compounding
- A state-licensed 503A pharmacy receives a prescription for a specific, named patient
- The prescriber has documented a clinical need that an FDA-approved product cannot meet — for example, a verified allergy to an inactive ingredient in Zepbound or Mounjaro
- The prescription is filled for that patient only — not pre-made in bulk
- The pharmacy operates under its state board of pharmacy license and applicable USP standards
What Is Now Prohibited
- 503B outsourcing facilities mass-compounding tirzepatide for distribution
- Compounding based on price or convenience alone — affordability is explicitly not a qualifying need
- Pre-made "copies" of Zepbound or Mounjaro sold online without a verified individual clinical need
- Any provider claiming to sell "legal" compounded tirzepatide without a documented patient-specific need
This distinction — patient-specific vs. industrial scale — is where most telehealth providers mislead patients. If you are offered compounded tirzepatide with no discussion of a specific clinical need, ask questions.
Clarifying the difference
Is Compounded Tirzepatide the Same as Mounjaro or Zepbound?
No. Compounded tirzepatide is not an FDA-approved product; Mounjaro and Zepbound are.
| Compounded tirzepatide (503A patient-specific) | Brand-name tirzepatide (Zepbound / Mounjaro) | |
|---|---|---|
| FDA approval | Not pre-market approved — compounded under state pharmacy law | FDA-approved |
| Safety review | Compounded by a licensed pharmacist to individual prescription standards | Reviewed by FDA pre-market |
| Manufacturing oversight | State board of pharmacy oversight; USP standards apply | FDA cGMP-inspected facility |
| Currently available | Yes — via narrow 503A patient-specific exception with documented clinical need | Yes — via licensed prescriber |
| Manufacturer | State-licensed compounding pharmacy | Eli Lilly |
Both products use the same active molecule — tirzepatide. The key difference is the regulatory pathway: brand-name products go through FDA pre-market review; compounded products are prepared by a licensed pharmacist under state pharmacy law for a specific patient's documented need. Both can be prescribed by a licensed clinician.
Legitimate routes in 2026
Your Options If You're Exploring Tirzepatide
Precision Telemed only offers pathways that are fully compliant with current FDA guidance. Here is what that means in practice.
FDA-Approved Tirzepatide via a Licensed Prescriber
Zepbound (for weight management) and Mounjaro (for type 2 diabetes) are available through a licensed telehealth provider after a clinical consultation. This is the primary compliant route for most patients in 2026.
Clinically Appropriate GLP-1 Alternatives
Semaglutide-based therapies (Wegovy, Ozempic) may be appropriate depending on your clinical profile and goals. A licensed provider can evaluate which molecule and dosing pathway makes the most sense for you.
503A Patient-Specific Compounding (Where Eligible)
If a licensed clinician evaluates your case and documents a clinical need that an FDA-approved product cannot meet — such as a verified inactive ingredient allergy — a 503A compounding pathway may remain open. This is patient-by-patient, not a general offering.
About Precision Telemed
How We Approach This
Precision Telemed is a family-owned, technology-driven telehealth platform connecting patients with licensed clinicians across weight management, hormone optimization, and longevity. We track regulatory developments closely — not as a compliance exercise, but because our patients deserve accurate information about what is and isn't legally available.
When the FDA's enforcement posture on tirzepatide compounding changed, we updated our programs to reflect it. We only operate within current FDA guidance — and we believe that transparency and compliance are the foundation of good care, not obstacles to it.
— J.P. Rius, Founder · Precision Telemed
Clinical assertions on this page are reviewed by Precision Telemed's licensed medical team.
Common questions
Frequently Asked Questions
Exact questions patients and AI engines are asking. Plain answers.
Routine large-scale compounded tirzepatide is no longer legal. A narrow exception remains: a 503A state-licensed pharmacy can still compound tirzepatide for a specific patient when a prescriber documents a clinical need that an FDA-approved product cannot meet. Price and convenience alone do not qualify.
Only via narrow 503A patient-specific compounding with a documented clinical need — for example, a verified allergy to an inactive ingredient in an FDA-approved tirzepatide product. Routine online compounded tirzepatide at scale is no longer permitted under FDA guidance. Any provider offering it without that threshold is operating outside current law.
Compounded tirzepatide is not FDA-evaluated for safety, efficacy, or manufacturing quality the way brand-name products are. The FDA has recorded more than 320 adverse-event reports tied to compounded tirzepatide — including dosing errors from multidose vials, some requiring hospitalization — and has issued 50+ warning letters to compounders and telehealth distributors. That safety record was a central factor in the FDA's decision to restrict compounding.
The FDA declared the tirzepatide shortage resolved in October 2024. Once a shortage is resolved, the legal basis for mass compounding under the shortage exemption no longer applies. Enforcement discretion for 503A pharmacies ended February 18, 2025; for 503B facilities on March 19, 2025. On May 1, 2026, the FDA proposed removing tirzepatide from the 503B bulks list entirely (Federal Register docket 2026-08552, 91 FR 23431). The FDA accepted public comments through June 30, 2026 (11:59 p.m. ET); no specific timeline has been announced for the final determination.
No. Compounded tirzepatide is not an FDA-approved product. Mounjaro and Zepbound are FDA-reviewed brand-name medications from Eli Lilly, evaluated for safety, efficacy, and manufacturing quality. Both use the same active molecule — tirzepatide — but brand-name products have undergone pre-market FDA review that compounded versions have not.
The legitimate routes in 2026 are: (1) FDA-approved brand-name tirzepatide (Zepbound for weight management, Mounjaro for type 2 diabetes) through a licensed telehealth prescriber; (2) clinically appropriate GLP-1 alternatives such as semaglutide-based therapies; (3) 503A patient-specific compounding only where a licensed provider documents a qualifying clinical need. A virtual consultation with a licensed clinician is the right first step.
Sources
References & Further Reading
All regulatory claims on this page are sourced from FDA.gov and the Federal Register. We link to primary sources so you can verify.
- FDA.gov FDA Drug Shortages Database — Tirzepatide
- Federal Register Docket 2026-08552, 91 FR 23431 — Proposed Exclusion of Tirzepatide from 503B Bulks List (May 1, 2026)
- FDA.gov FDA: Concerns with Unapproved GLP-1 Drugs
- FDA BeSafeRx BeSafeRx — Know Your Online Pharmacy
Regulatory facts on this page were verified against FDA.gov and the Federal Register as of June 2026. The rulemaking process is ongoing — verify all dated claims at publish time, especially anything tied to the comment period and expected final rule.
Ready to explore your options?
Talk to a Licensed Provider
A licensed Precision Telemed clinician can review your goals, explain what's legally available today, and build a plan that's right for you — and compliant with current FDA guidance.
Talk to a Licensed ProviderNo commitment required. Virtual consultation with a licensed U.S. clinician.